Shares of DBV Technologies SA – (NASDAQ:DBVT) gapped up before the market opened on Wednesday . The stock had previously closed at $35.76, but opened at $35.96. DBV Technologies SA – shares last traded at $36.43, with a volume of 32,822 shares changing hands.

DBVT has been the topic of several research reports. Leerink Swann reaffirmed a “buy” rating and set a $54.00 price objective on shares of DBV Technologies SA – in a research report on Tuesday, August 23rd. Zacks Investment Research raised DBV Technologies SA – from a “sell” rating to a “hold” rating in a research report on Wednesday, June 8th. Finally, Jefferies Group reaffirmed a “buy” rating on shares of DBV Technologies SA – in a research report on Wednesday, June 8th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. DBV Technologies SA – has an average rating of “Buy” and an average target price of $50.00.

The company has a 50 day moving average price of $34.79 and a 200 day moving average price of $33.04. The company’s market cap is $1.71 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/dbv-technologies-sa-dbvt-shares-gap-up-to-35-96.html

Several hedge funds and other institutional investors have recently made changes to their positions in the stock. FMR LLC increased its position in shares of DBV Technologies SA – by 1.3% in the second quarter. FMR LLC now owns 4,195,397 shares of the company’s stock worth $136,854,000 after buying an additional 52,664 shares during the last quarter. Deerfield Management Co. raised its stake in DBV Technologies SA – by 113.2% in the second quarter. Deerfield Management Co. now owns 1,743,229 shares of the company’s stock worth $56,864,000 after buying an additional 925,423 shares during the period. Alliancebernstein L.P. raised its stake in DBV Technologies SA – by 20.3% in the second quarter. Alliancebernstein L.P. now owns 794,220 shares of the company’s stock worth $25,907,000 after buying an additional 133,953 shares during the period. Perceptive Advisors LLC raised its stake in DBV Technologies SA – by 31.2% in the second quarter. Perceptive Advisors LLC now owns 546,696 shares of the company’s stock worth $17,833,000 after buying an additional 130,000 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in DBV Technologies SA – by 6.6% in the second quarter. JPMorgan Chase & Co. now owns 254,492 shares of the company’s stock worth $8,301,000 after buying an additional 15,849 shares during the period.

About DBV Technologies SA –

DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.

5 Day Chart for NASDAQ:DBVT

Receive News & Ratings for DBV Technologies SA - Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies SA - and related companies with MarketBeat.com's FREE daily email newsletter.